Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Neutral" at Robert W. Baird

Key Points

• Robert W. Baird downgraded Ultragenyx Pharmaceutical from “outperform” to “neutral” and set a $16 price target, implying roughly 39.7% downside from the reported $26.53 share price.
• Analyst sentiment remains mixed but leans positive: the stock has a consensus “Moderate Buy” rating and an average price target of $51.53, despite recent neutral and downgraded ratings from several firms.
• Ultragenyx exceeded quarterly expectations, reporting a $0.90 per-share loss versus the anticipated $1.22 loss and $214 million in revenue, up 28.5% year over year; however, it continues to post substantial negative margins and return on equity.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) was downgraded by stock analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating in a research note issued to investors on Thursday, Briefing.com reports. They currently have a $16.00 target price on the biopharmaceutical company's stock. Robert W. Baird's price objective would indicate a potential downside of 39.69% from the company's current price.

Other research analysts have also issued reports about the company. HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Ultragenyx Pharmaceutical in a report on Monday, August 10th. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 9th. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Guggenheim lowered their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. downgraded shares of Ultragenyx Pharmaceutical from an "overweight" rating to a "neutral" rating and set a $36.00 price target on the stock. in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $51.53.

Ultragenyx Pharmaceutical Stock Up 2.8%

Ultragenyx Pharmaceutical stock opened at $26.53 on Thursday. The firm has a 50-day moving average price of $28.36 and a two-hundred day moving average price of $25.08. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of -4.54 and a beta of 0.31. Ultragenyx Pharmaceutical has a 52-week low of $18.29 and a 52-week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. During the same period in the previous year, the firm posted ($1.17) earnings per share. The business's revenue was up 28.5% on a year-over-year basis. Research analysts expect that Ultragenyx Pharmaceutical will post -3.97 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of the business's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the sale, the executive vice president owned 94,462 shares of the company's stock, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the company's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the sale, the director owned 21,095 shares of the company's stock, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their position. The SEC filing for this sale provides additional information. 5.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Large investors have recently made changes to their positions in the business. Parallel Advisors LLC grew its stake in shares of Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,440 shares during the last quarter. Leonteq Securities AG lifted its stake in Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 1,333 shares during the last quarter. Versant Capital Management Inc boosted its holdings in Ultragenyx Pharmaceutical by 662.9% during the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 1,001 shares in the last quarter. Danske Bank A S bought a new stake in Ultragenyx Pharmaceutical during the third quarter worth approximately $39,000. Finally, EverSource Wealth Advisors LLC grew its position in Ultragenyx Pharmaceutical by 573.0% in the first quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 1,845 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source